Project Grant R44CA250872

The National Cancer Institute (NCI) awarded a $1,003,173 Project Grant under the Cancer Treatment Research program (CFDA 93.395) to Radiopharmaceutical Imaging And Dosimetry, LLC, a company based in Baltimore, Maryland. The funding supports the development of a prototype web/cloud-based quantitative SPECT reconstruction software system for use in clinical trials and ultimately clinical dosimetry for radiopharmaceutical therapy (RPT). The software aims to enable accurate quantitative imaging...

Grant Award Summary Fred Hutchinson Cancer Center received a $716,319 Project Grant from the National Cancer Institute (NCI) under the Cancer Treatment Research program (CFDA 93.395) awarded June 11, 2026, with an ultimate completion date of May 31, 2031. The grant funds research and development of optimized CD45-targeted Astatine-211 radioimmunotherapy (RIT) for malignant and non-malignant blood disorders. The research builds on prior Phase 3 clinical validation of Iodine-131-based CD45 RIT and...

Federal Project Grant Award Summary Neonc Technologies Holdings Inc. received a $399,998 Project Grant award from the National Cancer Institute (NCI) under the Cancer Treatment Research program (CFDA 93.395) on August 7, 2025, with a completion date of July 31, 2026. The award supports the development of NEO212, a novel oral anticancer drug designed to treat acute myeloid leukemia (AML). NEO212 is a small molecule created through covalent conjugation of two established anticancer agents:...

This $255,730 National Science Foundation project grant supports the development of self-assembling molecular brachytherapy for treatment of metastatic cancer. The goal is to enable radiation therapies for metastatic cancer, which accounts for approximately 90% of cancer deaths in the United States each year. The grantee, Oncurie, LLC, seeks to advance a radiotherapy approach that exploits cancer cells themselves as catalysts for therapeutic delivery. Specifically, the company will develop an...

This Project Grant from the National Institutes of Health National Cancer Institute totaling $1,170,174 was awarded to Trevarx Biomedical, Inc. on April 1, 2021 with a completion date of March 31, 2022. The grant supports development of an optimized synthesis platform for the radiotracer [18F]FTT under the Cancer Treatment Research program (CFDA 93.395). Specifically, the funding will allow Trevarx Biomedical and the University of Pennsylvania to determine the best method for synthesizing...

Federal Project Grant Award Summary The National Cancer Institute (NCI), under its Cancer Treatment Research program (CFDA 93.395), awarded The Johns Hopkins University a $591,419 Project Grant effective May 1, 2026 through April 30, 2031 to develop low molecular weight theranostics for multiple myeloma treatment and detection. The primary deliverables include the creation of a peptide-based, first-in-class theranostic pair targeting cluster of differentiation 38 (CD38) protein, which is...

Paramita Therapeutics Inc. received a $353,009 Phase I Small Business Innovation Research (SBIR) grant from the National Cancer Institute's Cancer Treatment Research program (CFDA 93.395), awarded September 24, 2025, with completion targeted for August 31, 2026. The project focuses on developing novel multivalent prostate-specific membrane antigen (PSMA)-targeted taxane-conjugates to address bone metastases in prostate cancer. The research involves synthesizing multivalent drug conjugates (MDCs)...

Federal Grant Award Summary The National Cancer Institute awarded The University of Iowa a $2,185,934 Project Grant on August 28, 2025, under the Cancer Centers Support Grants program (CFDA 93.397) to establish a Neuroendocrine Tumor Specialized Programs of Research Excellence (SPORE) in Human Cancer through July 31, 2030. This award supports innovative translational research addressing neuroendocrine tumors (NETs) and neuroendocrine carcinomas (NECs)—orphan cancers with increasing prevalence...

Federal Project Grant Award Summary The National Cancer Institute (NCI) awarded $431,222 to the Research Foundation of the City University of New York (RFCUNY), doing business as RFCUNY–Hunter College, under the Cancer Treatment Research program (CFDA 93.395) on May 13, 2026, with completion targeted for April 30, 2028. This project grant supports the development of radiotherapeutic paradigms for desmoplastic small round cell tumor (DSRCT), an extremely rare abdominal and pelvic soft tissue...

Grant Award Summary Nuvox Pharma, LLC received a $1.84M Project Grant from the National Cancer Institute under the Cancer Detection and Diagnosis Research program (CFDA 93.394), awarded September 22, 2025, with completion targeted for August 31, 2027. The award funds research to develop and validate liquid biopsy blood-based biomarkers for glioblastoma (GBM) patients undergoing chemoradiation therapy combined with dodecafluoropentane emulsion (DDFPE), an oxygen therapeutic agent. The research...